The heart-drug Multaq® , which an FDA report has linked to severe liver injuries , is now being cited for additional safety issues.
On the heels of the independent Institute for Safe Medicine Practices report that Multaq (dronedarone) was associated with more cases of slow heart beat; a rapid heart beat in the heart’s main chamber, and an uncontrolled arrhythmia in the atria than all other drugs the institute monitors, the
The Food and Drug Administration has taken action to keep people with permanent atrial fibrillation from taking Multaq®. The drug, sold by Sanofi-Aventis, is designed to prevent potentially deadly arrhythmia and make the heart beat normally.
The safety agency's latest advisory said that patients with a "permanent" version of the abnormal heartbeat called atrial fibrillation shouldn't get the medicine, generically called dronedarone. The FDA's said the drug "doubles the rate of cardiovascular death, stroke, and heart failure" in patients with permanent atrial fibrillation.
Sheller, P.C. is investigating potential claims for injuries related to the drug. If you or someone you know with permanent AF who has suffered heart failure, stroke, or cardiovascular-related death after taking Multaq®, contact us by e-mail at info@sheller.com, or call toll free 800-883-2299.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.